Aripiprazole Lauroxil

阿立哌唑十二烷酸酯

Report date: 2026/03/30 17:02:26

Base Information

Drug NameAripiprazole Lauroxil
Drug Alias Name月桂酰阿立哌唑月桂酸阿立哌唑AristadaALKS-9072ALKS-9070 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsSerotonin 1a (5-HT1a) receptor agonistsDopamine D2 receptor agonists
TargetsSerotonin 2a (5-HT2a) receptorSerotonin 1a (5-HT1a) receptorDopamine D2 receptor
Therapy Area/IndicationsSchizophreniaPsychotic DisordersAutistic Disorder +[5] 
Global Approved IndicationsSchizophrenia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2015/10/05
Country/TerritoryCzechiaBulgariaUnited States +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAlkermes Plc
China Registration ClassN/A

Develop Information

Active CompaniesAlkermes Inc
Inactive CompaniesJanssen-Cilag International NvDrexel University College of MedicineOtsuka Pharmaceutical Development & Commercialization Inc +[4] 
Active IndicationsSchizophrenia
Inactive IndicationsPsychotic DisordersAutistic DisorderBipolar Disorder +[4] 

Other Information

ATC CodeN05AX12
Related LinksWikipediaDrugBankKEGG